Breaking News Instant updates and real-time market news.

AGLE

Aeglea BioTherapeutics

$7.50

-0.28 (-3.60%)

04:55
10/15/19
10/15
04:55
10/15/19
04:55

Aeglea BioTherapeutics management to meet with Needham

Meeting to be held in the Midwest on October 15 hosted by Needham.

  • 15

    Oct

AGLE Aeglea BioTherapeutics
$7.50

-0.28 (-3.60%)

03/21/19
JPMS
03/21/19
INITIATION
Target $14
JPMS
Overweight
Aeglea BioTherapeutics initiated with an Overweight at JPMorgan
JPMorgan analyst Anupam Rama started Aeglea BioTherapeutics with an Overweight rating and $14 price target. Aeglea is an emerging player in the rare disease space and its lead asset pegzilarginase "has multiple de-risking points" for lead indication arginase 1 deficiency, Rama tells investors in a research note. This is a disease with a clear unmet need for which there are no approved therapies to directly target cause and limited competition, the analyst adds.
05/21/19
HCWC
05/21/19
INITIATION
Target $20
HCWC
Buy
Aeglea BioTherapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Edward White started Aeglea BioTherapeutics with a Buy rating and $20 price target. The company's capital raise in February removes the financial overhang from the stock, White tells investors in a research note. He believes Aeglea shares represent an attractive investment opportunity with several potential catalysts over the next 12 months.
09/03/19
HCWC
09/03/19
NO CHANGE
HCWC
Buy
Aeglea updated pegzilarginase data bodes well for Phase 3, says H.C. Wainwright
After Aeglea announced updated data from the company's Phase 1/2 trial and ongoing Phase 2 open label extension trial for pegzilarginase in the treatment of patients with arginase 1 deficiency, H.C. Wainwright analyst Edward White noted that the 20-dose data from 14 patients showed arginine control and an overall clinical response rate of 79%. The analyst, who thinks the data bodes well for the Phase 3 trial results, keeps a Buy rating on shares of Aeglea BioTherapeutics.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.